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INTRODUCTION
rachytherapy of cervix carcinoma often results in high doses
to surrounding structures, such as rectum and bladder.
Therefore, these organs should be closely monitored. The late
complications manifesting on these organs as a result of radio-
therapy can lower the therapeutic ratio and significantly decrease
patient quality of life. The most important treatment related factors
that could lead to creation of late complications on rectum include
total dose to the rectum, volume of irradiated rectum and dose
rate of brachytherapy modality used (1-4). Of those, particularly
important is the brachytherapy dose delivered to the rectum. All
said adds to significance of proper definition of the reference
points and the dosimetric methods used in intracavitary
brachytherapy (IBT) in predicting the probability of late effects and
in making comparative analyses. The International Commission
on Radiation Units and Measurements (ICRU), in Report No. 38
(5), came out with certain recommendations for reporting the
intracavitary treatment of carcinoma of the cervix. Apart from
introducing the concept of reference volume and use of air kerma
for source specification, the report also recommended standard
definitions for reference points for critical organs like bladder and
rectum. In ICRU method the posterior vaginal wall is visualized by
means of an intravaginal mould or radio-opaque gauze. The rectal
reference point is determined on a lateral radiograph, on antero-
posterior (AP) line drawn through either the lower end of the
intrauterine source or through the middle of the intravaginal
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BACKGROUND: Brachytherapy of cervix carcinoma often results in high doses to sur-
rounding structures, such as rectum and bladder. Therefore, these organs should be
closely monitored. Purpose of this work was to evaluate rectal marker made in our
institution for rectal dose measurements by comparing it with the method recom-
mended in ICRU (International Commission on Radiation Units and Measurements)
Report 38. 
METHODS: In this work rectal dosimetry was performed by two different methods. In
one, rectal marker made in Institute of Oncology Sremska Kamenica was used, while
in the other method recommended in ICRU Report 38 dose on ICRU rectal point was
measured.  A total of 34 applications using Microselectron HDR and its standard appli-
cator set were performed in a prospective way. The prescribed dose was 7.6 Gy to
point A for each application. Rectal doses were calculated by Nucletron Plato Treatment
Planning System.
RESULTS: Differences found between the means of ICRU point R and rectal marker
points Rref and Rmax were significant (P<0.002 and P<0.00002). The same result was
obtained for Rref and Rmax pair (P<0.003).
CONCLUSION: Maximal doses obtained using rectal marker were in most cases high-
er than those obtained by ICRU method. It conforms well to several CT-based dosime-
try studies where rectum dose was found to be higher from that obtained by ICRU
method.
KEY WORDS: Cervix neoplasms; Brachytherapy; Radiotherapy Planning, Computer-
assisted; Rectum
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253sources, 5 mm behind the posterior vaginal wall. It means that
according to these recommendations, rectal reference point is
determined by indirect marking (i.e. not using marking of the rec-
tum itself). Different radiotherapy centers use various methods in
order to determine absorbed dose on the anterior rectal wall,
which is the most exposed part of the rectum. The most frequent
techniques used for that purpose are:
* Recommended ICRU method
* In vivo dosimetry (i.e. measurement of absorbed dose in rec-
tum during IBT treatment)
* Injection of contrast and air combination directly into rectum
* CT based dosimetry
* Use of rectal marker
Purpose of this work was to evaluate rectal marker made in our
institution for rectal dose measurements by comparing it with the
method recommended in ICRU Report 38.
MATERIALS AND METHODS
The study was carried out in a prospective way and total of 34
applications using Microselectron HDR and its standard applica-
tor set were performed. The prescribed dose was 7.6 Gy to point
A for each application. Stages Ib2-IVa were treated with radical
irradiation (external beam irradiation and HDR brachytherapy) and
without hysterectomy. Patients received external beam irradiation
using 10 MV or 15 MV photons to a dose of 50 Gy in 30 fractions
over a 6 weeks period. Of these, the first 20 Gy in 10 fractions
were given with open fields and the remaining 30 Gy in 20 frac-
tions were given with a midline block. Size of the field was deter-
mined individually according to the stage and patient anatomy.
Brachytherapy part of the treatment was consisted of 5 HDR
weekly fractions of 7.6 Gy to point A. IBT treatment was carried
out on Microselectron HDR which uses 192Ir as radioactive
source. Activity of the source was in the range of 4-10 Ci in all 34
applications administered. Standard applicator set consists of a
tandem (15￿, 30￿ and 45￿) and two ovoids (15, 20 or 25 mm in
diameter). Rectal mucosa was marked using rectal marker made
in Radiotherapy Department of the Institute of Oncology, Sremska
Kamenica, while posterior vaginal wall was marked by means of
intravaginal radio-opaque gauze. IBT treatment planning was per-
formed on Nucletron - PLATO TPS for each insertion, based on
AP and lateral orthogonal radiographs. Rectal doses were calcu-
lated using 13.7 version of Nucletron’s - PLATO HDR
Microselectron treatment planning software.
Rectal marker (Figure 1) used in this study consists of flexible
plastic tube (b) (25 cm length, 7 mm diameter) on which one end,
rubber balloon is attached (a) (8-10 cm length) while on the
other, small faucet is mounted (c). Interior wall of the balloon is
impregnated by barium salt emulsion for the purpose of visual-
ization of rectum. After insertion of the marker into the rectum the
balloon is filled with 10 to 20 cm3 of air using syringe (d), and
faucet is closed. Posterior vaginal wall was also visualized by
packing vagina with radio-opaque gauze in order to be able to use
ICRU method of rectum wall dose determination. During treat-
ment planning, 5 to 10 representative points at the anterior rectal
wall were selected (at a distance of 3.5 mm one from another) on
lateral radiography. The points are selected symmetrically in rela-
tion to the anteroposterior line passing through the middle of the
intravaginal sources (on lateral radiography), at the same time
touching the surface of the rectal marker balloon (Figure 2). 
On AP radiography, rectal marker reference points are set along
the mid caudo-cephalad line on the rectal marker balloon (Figure
3). Rectal marker points were placed densely in order to better
estimate change of dose on them and to improve representation
of rectal volume occupied by potentially unacceptable dose. ICRU
rectal point (R) is set on AP radiography in the middle position,
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Figure 1. Rectal marker made in Institute of Oncology - Sremska Kamenica. a)
Rubber balloon (8-10 cm length). b) Flexible plastic tube (25 cm length, 7 mm
diameter). c) Small faucet. d) Syringe
Figure 2. Lateral radiograph where rectal marker reference point (Rref) and ICRU
rectal reference point (R) could be seenbetween two ovoids. Marker reference point (Rref) always lied at
the anteroposterior line drawn from the middle of intravaginal
sources and crossing the marker. On the same line also lied ICRU
rectal reference point R (Figures 2,3). 
Dose on marker point (Rref) was compared with ICRU rectal ref-
erence point (R). Point on marker that received maximal dose
(Rmax) was also compared with R (Figures 4,5). Some other con-
clusions were also drawn up on the basis of gathered data. 
Reconstruction method of PLATO software package allows very
accurate determination of the rectal reference points on lateral
radiography (order of magnitude 1 mm), using and comparing
their common coordinates on the AP radiography. Anterior rectal
wall reference points which have been specified and reconstruct-
ed this way, made possible assessment and calculation of rectal
mucosa dose exposure.
Taking into account that doses were determined on selected
points on rectal marker (Rref and Rmax) as well as on ICRU rectal
point R, it was not of particular importance to specify some cer-
tain source positions in tandem and ovoids. It was just important
for chosen source arrangement in applicator to be the same in
every application, which would enable comparison of doses on
specified rectal points from application to application. Within the
tandem, dwell positions were activated from the tip to the level of
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Figure 3. AP view where Standard Applicator set (tandem and two ovoids), rec-
tal marker, radio-opaque gauze and Foley balloon are visualized
Figure 4. Distribution of maximal doses (Rmax) along the rectal marker measured
positions expressed in %. Trend line is also included
Figure 5. a) Correlation (r) between dose on ICRU point R and dose on rectal
marker reference point Rref with regression line included. b) Correlation (r)
between dose on ICRU point R and dose on Rmax with regression line included.
c) Correlation (r) between dose on rectal marker reference point Rref and dose on
Rmax with their regression linetandem flange in the following manner: 1, 3, 5, 7, 10, 13, 16 etc.
(depending on the length of tandem used). Four dwells were acti-
vated within each ovoid and these active positions were 4, 5, 6,
and 7. Out of 34 executed applications, in just one, length of the
tandem was 30 mm. In 23 cases tandem length was 40 mm, 8
times it was 50 mm and in 2 cases tandem length was 60 mm.
Diameter of vaginal ovoids was 20 mm in 28 applications, while
in 6 cases it was 15 mm.
As already was mentioned, on lateral radiography 5 to10 repre-
sentative points at the anterior rectal wall were selected. These
points were placed so that they lay in the region of rectum, which
was the nearest to the radioactive sources. Amongst these 5 to
10 points, rectal marker reference point (Rref) as well as point on
marker that received maximal dose (Rmax) should have found its
place. This is the only reason that sometimes it was enough to
select only 5 points, while in some other situations more points
should have been marked in order to satisfy mentioned criterion.
Point Rref was fixed point and its position depended exclusively of
the middle position of intravaginal sources. On the other hand,
Rmax was moving point, because its position was the site on the
rectal marker that received maximal dose. Therefore, in some
cases position of Rmax was identical to the one Rref had, while in
others it could occupy position, which was up to 25 mm far from
Rref.
Statistical comparisons between rectal doses on rectal marker
(Rmax and Rref) and the doses on ICRU rectal reference point (R)
were made using paired t-test. Statistical significance was con-
sidered at the level of p<0.05.
RESULTS 
In Table 1 values of doses on chosen rectal marker reference
points (percents on prescribed dose to point A, i.e. percents nor-
malized to 7.6 Gy) are given. Bolded values represent doses on
Rref, while the biggest values in every row present Rmax for given
application (rectangle marked numbers).
Values shown in Table 1 were obtained by Treatment Planning
System calculations using its calculation algorithm. It could be
seen that in 6 applications (17.6 %) Rref was at the same time
Rmax, while in remaining 28 applications (82.4 %) distance
between the two was from 3.5 to 24.5 mm (taking into account
the fact that the distance between adjacent positions was 3.5
mm). Since rectal marker points (from R1 onwards) were placed
in caudo-cephalad direction, it could be concluded from Table 1
that in majority of cases, the part of the rectal marker that accept-
ed the highest doses (represented by Rmax) was placed cephalic
from point Rref (i.e. towards the tip of the tandem), while minori-
ty of cases had Rmax in caudal direction from Rref (i.e. towards
the end point of the tandem). Hence, out of 28 applications with
Rmax „ Rref in 18 cases (64.3 %) Rmax was above Rref and in 10
cases (35.7 %) it was below Rref (looking in caudo-cephalad
direction on AP radiography - Figure 2). In Figure 4, abscissa rep-
resented distribution of Rmax rectal points along the rectal mark-
er. Actually, part of the rectal marker (in mm) on which rectal
doses were measured was put on abscissa. On ordinate, fre-
quency of appearance of Rmax in different positions is given. Part
of the rectal marker, which was below reference rectal marker
point (Rref), had negative values on abscissa (towards end point
of the tandem), while positive values represented part of the
marker that was above point Rref. Reference rectal marker point
itself was placed in zero position. It can be easily noticed that sig-
nificant majority (67.6 %) of applications had Rmax in close prox-
imity of Rref (-3.5 to 3.5 mm), and that is the region which lies
exactly below middle positions of the intravaginal sources. It
means that using this rectal marker as rectal dosimetry instrument,
the same region accepted the highest doses as in case of ICRU
recommendations. Trend line in Figure 4 emphasizes that fact.
Just in one application Rmax was placed below tandem flange
(24.5 mm far from Rref). Doses on ICRU rectal point R were also
calculated using TPS. The way of determining position of R point
was already described in introduction and shown on Figure 2.
Baucal M.
' 2002, Institute of Oncology  Sremska Kamenica,Yugoslavia
256
Table 1. Doses on rectal marker points calculated by Treatment Planning System
(expressed in percents normalized to prescribed dose to point A)In Table 2 values of absorbed dose on ICRU point R were given
in Gy as well as in percents normalized to prescribed dose to
point A.  Absorbed doses on Rref and Rmax (also in Gy and %) are
given in the same table, this time independently, in order to make
comparisons between these three more simple. In the last two
columns absolute percentage dose differences between Rref and
R as well as between Rmax and R are given.
Results presented in Table 2 show that dose given to ICRU point
R was in majority of cases smaller than that given to both rectal
markers points (Rref and Rmax). In just 5 applications (14.7 %) R
received higher dose than Rmax, in 8 cases (23.5 %) R was big-
ger than Rref with which it can be compared directly, taking into
account they have the same y coordinate. Mean dose values for
R, Rref and Rmax were 5.03, 5.39 and 5.65 Gy, respectively.
When absorbed dose was given in percentages and normalized to
reference dose (7.6 Gy), mean dose values for R, Rref and Rmax
were 66.2 %, 70.9 % and 74.3 %, respectively. Mean absolute
percentage dose difference between Rref and R was 10.3 %, while
for Rmax and R it was 15.3 %. Differences between the means of
ICRU point R and rectal marker points Rref and Rmax were signif-
icant (P<0.002 and P<0.00002 respectively) and so was the
difference between the means of Rref and Rmax (P<0.003).
As it can be seen from Table 2, statistically significant differences
exist between R, Rref and Rmax. However, there is a very good
correlation between doses on these investigated rectal points,
which can be seen from Figure 5 (a, b, and c). Linear dependence
formula of the studied pairs is also given. The strongest correla-
tion exists between Rref and Rmax (r = 0.924), weaker is between
R and Rref (r = 0.872), and the weakest (but still very strong) is
between R and Rmax (r = 0.810). Very good correlation between
Rref and Rmax could be explained by already mentioned fact that
majority of applications (67.6 %) had Rmax in close proximity of
the point Rref (-3.5 to 3.5 mm). Majority of the points that diverge
from regression line in the pair R-Rref, does this because of sig-
nificant differences amongst z coordinates of the R and Rref
points, while significantly smaller number of deviations from
regression line is caused by differences that R and Rref have in
their x coordinates. Correlation of the pair R-Rmax is worse than
R-Rref correlation because in this case, the third coordinate (y) of
the points R and Rmax is also different.
DISCUSSION 
Specification of the region of rectal mucosa that absorbs the high-
est doses, based on empirical recommendations (such as ICRU
report 38) is valid just as a mean of comparison amongst radio-
therapy centers and under condition that all centers completely
obey the rules that are dictated by these recommendations. In
order to utilize all the benefits treatment individualization brings, it
is desirable to use the method of direct rectal visualization
employing rectal marker for that purpose. Accuracy of this
method depends mainly on the rectal marker design.
Rectal marker made in our institution completely meets following
constructional demands:
* It is inserted easily in rectal cavity and is adaptable to individual
anatomical conditions of the rectum.
* It adheres to anterior rectal wall in the region where the rectal
mucosa is closest to the radiation sources.
* It visualizes well on reconstruction radiographs and doesn’t
interfere (because of its negative contrast) with other marked ref-
erence points.
* Because of the small pressure it brings to rectal walls, marker
could not bring anterior rectal wall closer to sources and thus pre-
sent unrealistic picture.
There are not many studies that compare amount of dose
received by ICRU rectal point and the point that is placed on the
rectum and receives maximal dose and which could be estimat-
ed either by measurement (TLD or ionization chamber) or by TPS
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Table 2. TPS results of rectal dose measurements by rectal marker (Rref and
Rmax rectum anterior wall points) and ICRU method (R point)calculation. Serkies et al. (6) used in their comparative measure-
ments rectal marker made of lead wire and ICRU method. In some
centers, flexible wire rectal marker is usual way of marking the
rectum during intracavitary brachytherapy treatment (7,8).
Difference in calculated doses obtained by using these two meth-
ods was significant and the dose obtained by using ICRU method
was higher, on average by 15 % than the one obtained by using
lead wire rectal marker.
Deshpande et al. (9) reported that in about 70 % of applications
maximal rectal doses obtained using rectal marker and calculated
from orthogonal radiographs were in a range from 40-70 % of the
dose prescribed to point A.  However, measurements performed
by Stuecklschweiger (10) showed that the mean dose on rectum
measured by using flexible rectal plug (12 cm long and 2 cm
wide) was about 85 % of the dose prescribed to point A.  These
differences may originate from the fact that wire rectal marker is
inserted randomly in the rectal lumen (taking into account the fact
they can not fill whole rectal lumen because their diameter is
smaller), while flexible but firm marker can be set more precise
under the recto-vaginal septum. Therefore, specific rectal points
determined this way could not represent rectal wall. Lahtinen (11)
also obtained lower values of the doses on rectal points that were
visualized by injecting the contrast medium directly into rectum
(doses were calculated by TPS), than these obtained by the same
author on ICRU rectal point. Dose on ICRU point was higher on
average by 19.9 % from the maximal rectal dose that was
obtained using contrast medium and calculated by TPS.
It could be seen from the Table 2 that this study, that was carried
out in Institute of Oncology Sremska Kamenica, produced some-
how different results from the above mentioned studies. Our rec-
tal marker was designed in different manner than mentioned
markers, since it was made that way to fill completely part of the
rectal lumen that is located in the area closest to radioactive
sources and its balloon is flexible enough to follow precisely ante-
rior rectal wall. Knowing that, it is to be expected for doses on
rectal marker surface (Rref and Rmax) to remain higher than in
case of rectal markers used elsewhere. Doses on rectal marker
points were even higher from that, received by ICRU point (R), on
average for 15.3 %. Accordingly, it has been demonstrated that
doses on ICRU point and point on rectal marker that received
maximal dose, differed significantly. That is in good agreement
wit the results of several studies, where comparison was per-
formed between the doses on ICRU point obtained using orthog-
onal radiographs and doses on maximally exposed rectum point
which dose has been calculated using CT imaging (i.e. CT plan-
ning). Kapp (12) in his comparative study has got the maximal
dose on rectum using CT based treatment planning, that is 1.4
times (40 %) higher than that received by ICRU point. Fellner (13)
in similar study got 1.5 times higher dose using CT method, while
Ling (14) for the same ratio obtained number 1.9. Schoeppel (15)
has found out by examining dose-volume histograms obtained
using CT-planning, that maximal dose on rectum is 1.6 times
higher than that predicted by ICRU method.
As the majority of mentioned studies show it is insufficient to cal-
culate dose in just one point of the rectum (as is recommended
by ICRU). It is necessary to mark several points along the most
exposed region of the rectum, in order to obtain real information
where the maximally exposed region is, and also to enable calcu-
lation of the rectum volume that receives unacceptably high
doses. That task can be accurately done just by using CT based
treatment planning, while by using rectal marker for that purpose
just approximate values could be obtained. On the other hand, by
using just one rectal reference point, that information is impossi-
ble to obtain.￿eting￿z (16) reports that the most exposed region
of the rectum is located along the points of rectal marker that cov-
ers the length of 1.5-3 cm.  Conclusions of some CT based stud-
ies (12,14) were that dose distributions of intracavitary implants
put maximal rectal doses in points that were different from these
recommended by ICRU report 38. From the Table 1 and Figure 4
it could be seen that similar conclusion might be drown in the
case of this study as well. For instance, of 34 applications, just in
6 cases Rmax was in same position as Rref, while in 28 applica-
tions Rmax was placed cephalically or caudally from Rref (18-
cephalically, 10-caudally). However, it should be said that signif-
icant majority of applications in this study (67.6 %) had Rmax in
very close proximity of Rref (-3.5 to 3.5 mm) i.e. in the region that
lies under mid positions of the vaginal sources.
From the CT based dosimetry studies it is well known that precise
localization of the rectum is possible to obtain just by means of
analyzing individual CT slices (15). Since brachytherapy applica-
tions based on imaging techniques are time consuming, expen-
sive, hardly reproducible and can not be performed in all centers,
hence, it is not easy to introduce them in daily clinical practice
(for every patient and every application). Therefore, there is a
need for invention of some simple method that could still be accu-
rate enough, so it could be used in daily clinical practice. As far
as ICRU rectal reference point is concerned, it is obvious that the
point of this kind can not represent well rectal volume and thus,
can not serve as a control tool when radiation consequences of
the normal tissues are in question (15,17). Whether the dose on
ICRU rectal point can serve as a reliable signal for development of
late complications is still unclear. Some authors found that kind
of correlation (1,18,19), while some others did not succeed in
finding any significant correlation between dose received by ICRU
rectal point and development of rectal complications (3,20-22). 
Rectal marker of a good quality is satisfactory device for rectal
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Baucal M.dosimetry to be used in transitional period from ICRU recommen-
dations to CT-MRI based concept of brachytherapy planning. This
one, made in Radiotherapy Department of the Institute of
Oncology in Sremska Kamenica, according to the results of this
study, certainly falls into the category of rectal markers of a good
quality and as that, it can satisfy criteria of accurate determination
of absorbed dose on this critical organ. In the future, when appli-
cation of imaging techniques becomes accessible to all centers,
it will certainly replace methods of brachytherapy treatment plan-
ning used to date. When that happens, it will become possible to
further increase the dose to target volume, while at the same time
decreasing the dose to surrounding normal tissues.
CONCLUSION
As far as comparison of rectal marker points with ICRU rectal ref-
erence point is concerned the following conclusions could be
drawn:
- Maximal doses obtained using rectal marker were in most cases
higher than those obtained by ICRU method.
- Nevertheless, position of Rmax point corresponds well with Rref,
which lies on the same line as ICRU rectal point. That means this
region usually receives the highest dose. However, single point
reference dose is not enough and multiple points must be deter-
mined over the length of the applicator. This is especially valid
when rectum lies sideways from the applicator, which can signif-
icantly affect the estimated dose on it.
- Difference between ICRU dose point and doses on rectal mark-
er points conforms well to several CT-based dosimetry studies
where rectum dose was found to be higher from that obtained by
ICRU method.
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